Marian G. Michaels, M.D., M.P.H.

  • Professor of Pediatrics and Surgery

Marian Michaels, MD, MPH, a physician pediatric infectious diseases at Children’s Hospital of Pittsburgh and a professor of pediatrics at the University of Pittsburgh School of Medicine, with a secondary appointment in the department of surgery. Dr. Michaels research revolves around several aspects of infectious disease including infections associated with transplantation, neonatal and congenital infections as well as acute respiratory infections.

She has served on a number of national and international committees regarding infections and transplantation. 

Michaels has mentored many medical students and residents on scholarly projects, including students investigating infections in immunocompromised hosts, and antimicrobial stewardship. CMV and EBV infection and problems with families refusing vaccinations,

Major Lectureships and Seminars

  • Infections and ECMO. 8th Annual Neonatal and Pediatric ECMO Educational Conference UPMC Children’s Hospital of Pittsburgh. Pittsburgh, Pa., Aug 2, 2016
  • Emerging Infections after Pediatric Solid Organ Transplantation. Invited Speaker. 5th World Congress Pediatric Gastroenterology, Hepatology and Nutrition. Oct 6, 2016, Montreal Canada
  • Pediatric Antimicrobial Stewardship: Lessons learned. Invited Speaker One Health Seminar. Annual Get Smart Week. 2016 Penn State, State College, Pa., Nov 15, 2016.
  • Increased Risk Donors in the Era of A Drug Overdose Epidemic. Organ Donation Symposium. Finger Lakes Donor Recovery Network and University of Rochester Medical Center. Rochester NY. May 6, 2017.
  • Chair, International Pediatric Transplant Association (IPTA), Session infectious Diseases Barcelona, Spain May 27, 2017.
  • Speaker, CMV Update Plenary session. International Pediatric Transplant Association (IPTA) Barcelona, Spain May 27, 2017.
  • Chair, International Pediatric Transplant Association. (IPTA) Session Epstein Barr Virus Barcelona, Spain May 28, 2017,
  • Speaker, Public Health Service PHS Increased Risk Donors: Putting it All Together. American Society of Transplantation Fellows Symposium on Transplantation Sept 15-17, 2017 Grapevine TX.
  • Speaker, Matching the Patient to the Donor in Pediatric Transplantation. American Society of Transplantation Fellows Symposium on Transplantation Sept 15-17, 2017 Grapevine TX.
  • Speaker, the Microbiome, Infection, and Alloimmunity. American Society of Transplantation Fellows Symposium on Transplantation Sept 15-17, 2017 Grapevine TX.
  • Panelist/Speaker meet the Professor. Rapid Fire Transplant ID Cases. Infectious disease Society of America Annual IDweek San Diego CA Oct 6, 2017
  • Panelist/Speaker- And the Infectious Disease Consultant says, “What?”... Infectious disease Society of America Annual IDweek San Diego CA Oct 7, 2017
  • Speaker. Infectious Issues of Xenotransplantation. Infectious disease Society of America Annual IDweek San Diego CA Oct 7, 2017
    • Speaker Sunrise symposium Should I Accept this Organ? When to call your ID colleagues at 2 AM for known Infections in the Donor. American Transplant Congress 2018 Seattle WA June 4, 2018
    • Speaker/Moderator Midday Lunch and Learn. Symposium. Prevention and Management of Long Term Viral Infections. American Transplant Congress 2018 Seattle WA June 4, 2018
  • Webinars:
    • A to Zika  Panelist  DTAC, Organ Procurement and Transplantation Network (OPTN).  2016
    • Improving post transplant communication of new donor information. Panelist.  DTAC/OPTN Aug 8, 2016 
    • Zika virus an Update on Transplant Concerns. Speaker New York State Department of Health. Sept 29, 2016
    • DTAC and CDC Collaborative Case Reviews. Speaker. OPTN/UNOS. Oct 4, 2016
    • DTAC: National Webinar on Guidance Explaining Risk Related to Use of Increased Risk Donor Organs When Considering Organ Offers. April 4, 2017
    • Adolescent HIV a Tale of Two Groups. Webinar. Speaker Pennsylvania/Mid Atlantic AIDS Education and Training Center PA/Western PA. April 19, 2017
    • The When, What and How for successful informed consent of transmissible diseases. Speaker. Organ Procurement and Transplantation Network (OPTN).  August 16, 2018

Professional Affiliations/Society Memberships

  • Alpha Omega Alpha Honor Medical Society
  • American Academy of Pediatrics
  • Infectious Diseases Society of America
  • Pediatric Infectious Diseases Society
  • American Society of Transplantation
  • American Society for Microbiology
  • Society for Pediatric Research
  • International Pediatric Transplantation Association

Education & Training

  • University of Pennsylvania School of Medicine- M.D.
  • Great Ormond Street Hospital for Children/NHS Trust/ Children's Hospital of Philadelphia- Residency
  • University of Pittsburgh School of Medicine- Fellowship, Pediatric Infectious Diseases
  • University of Pittsburgh Graduate School of Public Health. MPH

Representative Publications

Research Interests

Marian Michaels’ work has focused on four major areas: congenital/newborn infections; infections in immunocompromised hosts, including patients receiving solid-organ and bone marrow transplants, children on immunosuppressive medications, and children with HIV; immunizations; and more general pediatric infectious diseases including acute viral infections; and antibiotic treatment and antimicrobial stewardship.

Michaels was funded by the CDC as a subcontract to the Department of Family Medicine (PI: Richard Zimmerman) to evaluate influenza vaccine efficacy in hospitalized patients. The CDC funded five sites across the country for ambulatory vaccine efficacy, but only two sites (Pittsburgh under Michaels and the University of Michigan) were funded for the inpatient study. The Division was the only pediatric program and the work led to the funding listed below as part of the pediatric consortium. As an outgrowth of this study, Michaels is analyzing data that should lead to three papers this coming year, 1) influenza vaccine efficacy for inpatients compared to ambulatory patient groups, 2) attitudes to influenza vaccination and plan for future vaccines; 3) a survey on decision making for obtaining respiratory viral panels. 

Michaels is co-PI on a CDC-sponsored grant submission along with John Williams to be a center for the New Vaccine Surveillance Network (NVSN). This study conducts prospective, population-based surveillance for acute gastroenteritis and acute respiratory illness among hospitalized children to elucidate the epidemiology of acute infections in the pediatric population and to evaluate vaccine efficacy, including inpatient influenza vaccine efficacy.

The “Natural History of CMV-related Hearing Loss and Feasibility of CMV Screening as Adjunct to Hearing Screening in the Newborn (CHIMES)” study was funded through the National Institute on Deafness and Other Communication Disorders. This study is the largest congenital CMV screening study to date. Although the funding period has ended, the study continues to be a source of publications and presentations at international meetings, e.g., the Pediatric Academic Societies meeting.

Michaels continued her NIAID supported congenital CMV work as the site PI for “A Phase III, Randomized, Placebo-controlled, Blinded Investigation of Six Weeks Versus Six Months of Oral Valganciclovir Therapy in Infants with Symptomatic Congenital Cytomegalovirus Infection” (Collaborative Antiviral Study Group [CASG] 112). This study showed longer therapy to be superior for symptomatic infants with Congenital CMV infection. This study has led to two further investigations. The first is sponsored by NIAID as a BAA with Michaels as a subcontract to the University of Alabama and will address the treatment of asymptomatic infants with congenital CMV to prevent hearing loss. The second BAA funded by NIDCD will be a treatment trial for infants with hearing loss as the sole manifestation of congenital CMV infection. Michaels is Co-investigator overseeing of treatment and clinical management of all enrolled infants. (Site PI: David Chi, Otolaryngology).

The collaboration with UAB is been quite fruitful and Michaels is the site PI for two other studies as a subcontractor regarding infants and infection. One is a BAA to look at the pharmacokinetics of ganciclovir for very premature infants. The other is a BAA to do long-term follow up on newborns with neonatal herpes. Michaels is acting as a no-cost consultant for a third UAB study at Magee-Womens Hospital that is performing rapid screening of women in labor for herpes simplex virus shedding. It is anticipated that after this first screening study, a larger study will follow the infants born to these women. Michaels will serve as the co-PI with Harold Wiesenfeld.

Outpatient Early-intervention Services with Respect to HIV Disease for Children, Women, Youth, and Families. (2H76HA00079) The major goals of this project are for planning, capacity building, and providing care and preventive strategies for HIV infection in children and adolescents in Western Pennsylvania. This continues to support the HIV pediatric center, supporting a 50% full-time-equivalent social worker dedicated to caring for these families and 10% of a faculty salary to oversee the care of these children. Starting in July 2013, this funding source moved from Pitt to UPMC.

HIV Early-intervention Project for Children, Youth, Women, and Families. (2H12HA23029-07) The major goal of this project is to improve access to care and supportive services for HIV-infected women, infants, children, and youth. This grant supports the HIV pediatric center, supporting a 25% full-time-equivalent social worker dedicated to caring for these families and 10% of a faculty salary to oversee the care of these children. Starting in July 2013, this funding source moved from Pitt to UPMC.

Optimizing Outcomes after Pediatric Heart Transplant. (NIH/ National Heart, Lung, and Blood Institute: 1P50HL74732-01) The major goal of this project is to better understand the occurrence of allosensitization in pediatric heart transplant recipients and develop strategies for treatment. Michaels’ role has been to develop uniform monitoring protocols to be used across centers regarding infections, prevention, and treatment and to review and analyze results.

Michaels and Green serve as site Co-PIs for a BAA out of Children’s Hospital of Philadelphia to better understand adenovirus infections in pediatric stem cell recipients. We have just started enrollment.

Green and Michaels are co-PIs for a BAA out of Northwestern University that will be double-blind, placebo-controlled treatment study for immunocompromised hosts infected with norovirus. We anticipate starting to enroll early next year

Antimicrobial Stewardship. Michaels serves on the steering committee for the CHP ASP. One of the Division’s recently graduated pediatric residents completed a scholarly project during which she and her group analyzed Children’s Hospital’s use of piperacillin/tazobactam; they examined the appropriateness of initially starting and subsequently continuing its use beyond day three. Results of this study were published in the Journal of the Pediatric Infectious Diseases Society in 2015. In addition, a manuscript describing Michaels’ novel ASP Therapeutic Drug Monitoring (TDM) program was recently published is in the Journal of the Pediatric Infectious Diseases Society.

Unfunded studies

A productive collaboration has developed over the last several years of pediatric infectious disease physicians in the United States interested in answering research questions that cannot be answered at a single site. It grew out of the St Jude’s/Pediatric Infectious Disease Society annual meeting and has led to collaborations looking at respiratory viral infections (paper in revision). In addition, we have just finished entering data on C diff infections in this population to look at the epidemiology and anticipate presenting and publishing next year. Finally, the group has launched several retrospective studies that have led to presentations at national and international meetings as well as peer-reviewed manuscripts. In addition, an investigator-initiated project in collaboration with industry to look at CMV T-cell responses that should prove very exciting and lead to preliminary data for future NIH support.